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Abstract: Bacterial vaginosis (BV) is a complex vaginal infection most commonly associated 
with women of child-bearing age. Risk factors for BV are numerous. There are currently multiple 
clinical and laboratory tests for diagnosis of BV, including the most commonly used diagnostic 
methods: Amsel’s criteria or Nugent’s Gram stain scale. The mainstay of BV therapy is metroni-
dazole, but tinidazole as well as a few other agents have also been used successfully. Tinidazole is 
the second nitroimidazole antiprotozoal agent and a structural derivative of metronidazole. With 
a favorable pharmacokinetic profile and reduced side effects, tinidazole is an alternative agent 
for BV treatment. There are minimal head-to-head comparative data to establish tinidazole’s 
superiority to metronidazole or other therapeutic agents. Available data suggest tinidazole has 
a role in special populations particularly for refractory or relapsing BV.
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Bacterial vaginosis
Bacterial vaginosis (BV) is considered the most common cause of vaginitis in women 
of childbearing age.1 Previously called nonspecific vaginitis, Haemophilus vaginitis, 
anaerobic vaginitis, and Gardnerella-associated vaginal discharge, BV is associated 
with a complex change in vaginal flora. The changes in vaginal flora include decrease in 
Lactobacillus species number, specifically decreasing the hydrogen-peroxide producing 
organisms, and increase in Gardnerella vaginalis, Prevotella spp., Bacteroides spp., 
Mobiluncus spp., Mycoplasma hominis, peptostreptococcus and/or anaerobic gram 
negative rods.2
Sexual activity is associated with BV although not all patients with BV have this 
risk factor.1 Use of vaginal douching, intravaginal nonoxynol-9 spermicide and a 
new sexual partner are associated with a loss of vaginal colonization by normal flora. 
Use of intrauterine devices, non-White race, and prior pregnancy are additional risk 
factors for BV.1
Symptoms of bacterial vaginosis
The most common BV symptom is a characteristic off-white, homogenous and 
thin vaginal discharge that frequently smell of fish.4 There is little pruritus or 
inflammation associated with BV. Two different diagnostic tools are used when BV 
is suspected, Amsel’s criteria and Nugent Gram stain score. The presence of three of 
the four Amsel’s criteria has been considered diagnostic for BV. Those criteria are 
homogenous discharge, pH  4.5, positive amine test and/or presence of clue cells Therapeutics and Clinical Risk Management 2009:5 486
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on saline microscopy.4 Nugent and colleagues published 
a scoring system for the diagnosis of BV based on a 
Gram-stain vaginal smear. A score is assigned to the vaginal 
flora on a weighted continuum from 0 to 10 based on large 
Gram-positive rods, small Gram-negative or variable rods, 
or curved rods morphotypes.5 Culture of the discharge is not 
useful but molecular methods are currently being evaluated 
to diagnosis this condition. A DNA probe for G. vaginalis is 
already available and detects high numbers of G. vaginalis 
organisms only to differentiate BV from G. vaginalis vaginal 
colonization.
Targeted polymerase chain reaction (PCR) has recently 
been studied for detection of vaginal bacteria associated with 
bacterial vaginosis. As reported by Fredricks and colleagues 
who developed a series of taxon-directed 16S rRNA gene 
PCR assays for more sensitive detection of key vaginal 
bacteria. The goal of the research was to determine the preva-
lence of each species in the vagina, its association with BV, 
and the utility of PCR for microbiological diagnosis of BV. 
Seventeen targeted PCR assays were made for vaginal bacte-
rial species and tested against 264 samples of 81 subjects with 
BV and 183 subjects without BV.3 Leptotrichia/Sneathia, 
Atopobium vaginae, Megasphaera species, and three bacteria 
in the order of Clostridiales are significantly associated 
with BV. PCR detection of either a Megasphaera species 
or one of the Clostridiales bacteria yielded a sensitivity of 
99% and specificity of 89% for diagnosis of BV compared 
to the Amsel’s clinical criteria and sensitivity of 96% and 
a specificity of 94% compared to Nugent criteria. With this 
study, PCR detection of one or more fastidious bacterial 
species has been shown to be more reliable indicator of BV 
than cultures for detection of bacteria, such as G. vaginalis, 
highlighting the potential of PCR for the diagnosis of BV. 
Although this novel diagnostic procedure appears to be more 
effective in detecting BV; it lacks practical feasibility in the 
clinic and will likely by used in research studies only.3 This 
study provided much needed information as to the microbi-
ology of BV, opening up the opportunity for new insights 
into its pathogenesis.
Available therapy for bacterial 
vaginosis
The mainstay of BV therapy has been metronidazole, 500 mg 
by mouth twice daily or 750 mg extended release by mouth 
once daily for seven days. Treatment of male partners 
with metronidazole has not reduced the rate of recurrence 
among affected women.2 Alternatives to oral metronida-
zole include: vaginal therapies with 2% clindamycin or 
0.75% metronidazole. Recurrence within three months is 
common and is associated with 30%–40% of all cases of 
BV. Tinidazole, an antimicrobial agent initially used for 
Trichomonas vaginalis infections has also been shown to 
be effective for BV.6
Tinidazole
Tinidazole was recently introduced to the United States 
in order to combat metronidazole-resistant vaginal tricho-
moniasis. This agent also has other uses outside of vaginal 
infections such as Clostridium difficile-associated diarrhea;7 
chronic refractory pouchitis;8 giardiasis;9 and treatment of 
Helicobacter pylori infections.10 It is the second nitroimid-
azole antiprotozoal agent and is a structural derivative of 
metronidazole by replacement of  a 2-(hydroxyl)ethyl group in 
the 5-nitroimidazole backbone with a 2-(ethylsulfonyl)ethyl 
moiety.11 Tinidazole is a prodrug that is converted to its 
active form by reduction of its nitro group to toxic radicals 
via the ferredoxin-mediated electron transport. This reduc-
tion reaction causes a gradient for increased permeability of 
tinidazole molecules to enter the cell resulting in increased 
toxicity and antimicrobial activity.11
Pharmacokinetics of tinidazole
Tinidazole is available via intravenous infusion, oral, rectal, 
or intravaginal administration, but is currently only available 
orally in the United States.12 Absorption is different based on 
which type of administration is used, with oral administra-
tion having 90% bioavailability.13 Rectal administration 
resulted in 39% bioavailability while intravaginal adminis-
tration resulted in 10% bioavailability.
Approximately 12% of tinidazole is protein-bound and it 
diffuses into most tissues.13 Steady-state tissue site concentra-
tions of cerebrospinal fluid (CSF), abdominal sites (such as 
bile, intestinal mucosa and peritoneum), gynecological sites 
(vaginal secretions, uterine and fallopian tubes), dental bone 
and saliva are similar to corresponding serum concentra-
tions.13 Specifically, CSF penetration is excellent without 
inflamed meninges.14 After single intravenous infusion, 
tinidazole’s half-life is approximately 14 hours and a volume 
of distribution of 39 liters, compared to metronidazole’s 
half-life of about seven hours and volume of distribution 
of 46 liters.14
Distribution and elimination of tinidazole into the human 
body is through first-order kinetics. When given via intra-
venous infusion, 37% of tinidazole dose is recovered in the 
urine, with 25% as unchanged drug, 10% as a glucuronide 
conjugate, and 2% as the 2-hydroxymethyl metabolite.15 Therapeutics and Clinical Risk Management 2009:5 487
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Metabolism of tinidazole is via the cytochrome P450 
3A4 and 2B6 isoenzymes, with 2B6 having a lesser effect 
than 3A4.16
Microbial spectrum of tinidazole
Tinidazole is effective against anaerobic protozoal parasites, 
such as T. vaginalis, Entamoeba histolytica and Giardia 
duodenalis (also known as Giardia lamblia) and anaerobic 
bacteria, including B. fragilis, Clostridium perfringens, 
and Fusobacterium spp.17 Against typical vaginal flora, 
G. vaginalis and Lactobacillus, resistance to tinidazole is 
detected in 54% of G. vaginalis and 96% of Lactobacillus. 
There is minimal tinidazole resistance associated with 
Anaerococcus spp. and Prevotella spp.18 Tinidazole is dosed 
as a single 2 g dose by mouth when used for trichomoniasis 
and giardiasis or 500–1000 mg by mouth multiple times a 
day for 7–14 days when used for amebiasis.11
Adverse events profile for tinidazole
Adverse effects associated with tinidazole most commonly 
involve the gastrointestinal tract causing nausea, metallic 
taste, dyspepsia, epigastric discomfort, anorexia, and 
vomiting. Compared to metronidazole therapy, tinidazole is 
better tolerated.11 Weakness, fatigue, and malaise as well as 
dizziness make the central nervous system the second most 
common area for adverse effects.11
Tinidazole use for bacterial 
vaginosis
Tinidazole’s use for bacterial vaginosis and efficacy 
comparison with other agents is limited. It was evaluated 
by Ekgren and colleagues to assess clinical efficacy using 
different dosages and duration. Tinidazole was given as a 
single dose and on two consecutive days for the treatment of 
bacterial vaginosis in this randomized, double-blind study. 
The three study groups included tinidazole 2 g as a single 
dose (T1) versus tinidazole 2 g on two consecutive days (T2) 
versus placebo (P). Cure was determined by the absence of 
clue cells or Gardnerella vaginalis and was 51%, 74%, and 
4%, respectively for each study group. The difference between 
the placebo group and each of the two treatment groups was 
statistically significant (p  0.001) but there was no statisti-
cally significant difference between the two tinidazole treat-
ment groups. The number of adverse effects reported was 
44%, 39%, and 22% in the groups, respectively. The differ-
ence when compared to placebo was statistically significant 
for both T2 and T1 (p  0.05), but not statistically significant 
between T2 and T1 groups. Although only a numerically 
higher cure rate was detected in the second day of the therapy 
group and approximately the same frequency of adverse 
events; it was concluded that the two-day regimen was more 
efficacious than the one-day regimen or placebo.19
Another evaluation to optimize dosing for tinidazole 
was studied by Livengood and colleagues. The objective of 
this review was to assess the effectiveness between 21 and 
30 days after tinidazole administered orally 1 g once daily 
for five days versus 2 g once daily for two days, as well as 
comparing both regimens to placebo for the treatment of 
bacterial vaginosis. Two hundred thirty-five patients were 
evaluated and superior efficacy was demonstrated with both 
study regimens compared to placebo; with cure rates of 
36.8% (1 g daily regimen), 27.4% (2 g daily regimen), and 
5.1% (placebo), respectively. Adverse events occurred with 
comparable frequency in tinidazole and placebo recipients, 
except for dysgeusia, which was more common in both tini-
dazole arms, and nausea, which was more common in the 2 g 
tinidazole group. Although the tinidazole groups had more 
adverse events compared to placebo, the Fisher exact test 
gave p-values of 0.426 and 0.113 for the 1 g and 2 g groups, 
respectively. Only one serious adverse event, a perineal 
abscess, was seen in the placebo group and the patient was 
withdrawn. Overall, no patient withdrew because of unac-
ceptability of tinidazole treatment. This study supported the 
use of either regimen for treatment of bacterial vaginosis.6
Tinidazole has also been shown to be effective when 
administered intravaginally. A prospective randomized 
trial evaluated treatment of bacterial vaginosis with tinida-
zole vaginal tablets.20 It compared three regimens: (1) oral 
tinidazole 150 mg twice daily for seven days, (2) same oral 
treatment as (1) but the partner also received 500 mg twice 
daily for four days, or (3) intravaginal tinidazole 500 mg at 
bedtime for 14 days. After initial randomization, patients 
were reassessed at one and three months. The most benefit 
was seen at three-month follow-up was in treatment group 
3; where 70% of patients were asymptomatic compared to 
42% and 43% in groups 1 and 2 (p  0.05). This study also 
showed that intravaginal tinidazole was beneficial particu-
larly in patients with intrauterine contraceptive devices with 
80% of group 3 responding while 30% and 29% of group 1 
and 2 responding. A limitation of this study was the relatively 
low dose of tinidazole compared to the previously discussed 
two studies. Assumptions on relatively efficacy between oral 
and vaginally administered tinidazole should not be made 
based on this study only.
Vutyavanich and colleagues evaluated the treatment 
of tinidazole in the sexual partners of females with Therapeutics and Clinical Risk Management 2009:5 488
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bacterial vaginosis. The objective was to determine whether 
a single oral 2 g dose of tinidazole for women with clinically 
diagnosed bacterial vaginosis and their partners increases 
the cure rate as compared with the same treatment for the 
female patients alone. Results indicated there were no statisti-
cally significant differences in symptomatic improvement, 
clinical cure rates, or culture results between the two study 
groups. Therefore, based on this and several other studies, 
routine treatment is not recommended for male partners 
of women with bacterial vaginosis including those with 
recurrent disease.21
Milani and colleagues evaluated the efficacy of oral 
tinidazole and the use of an acidic vaginal gel compared to 
vaginal clindamycin alone. Sixty-four patients were included 
and randomized to one of two treatment groups: (1) oral 
tinidazole 2 g single dose, then after one week, acidic vaginal 
gel 2 g every three days for an additional three weeks versus 
(2) vaginal clindamycin 2% gel once daily for seven days. 
Results of study were two-fold; in the short term, the two 
regimens were equally effective, but with the additional of 
the acidic vaginal gel to the tinidazole regimen, the tinidazole 
regimen was found to result in lowering vaginal pH and 
achieved higher normalization rates in laboratory tests at 
zero-month follow-up. Clinical cure rate was defined as the 
absence of at least two of the four signs of BV, according 
to Amsel’s criteria. Laboratory cure rate was defined as a 
clinical cure plus a negative result of the BV-blue (OSOM 
BVBlue; Genzyme Corp., Cambridge, MA, USA) and whiff 
test. The study concluded that treatment of BV with single 
oral dose tinidazole was at least as effective as the seven-
day of vaginal clindamycin regimen. Since oral tinidazole 
has also been found to effective as a standalone agent, it is 
also unclear if the acidic vagina gel had a long term clinical 
benefit in this study.22
Another comparison of a tinidazole-containing regimen 
versus complementary and alternative medicine regimen 
was compared by Baylson and colleagues.23 The aim of this 
study was to compare the efficacy of Praneem, a polyherbal 
pessary, versus Ginlac-V pessary, a therapy containing 
clotrimazole, tinidazole and lactobacilli, for treatment of 
women with symptomatic vaginal discharge. One hundred 
patients were randomized to one of the two treatments 
groups. Overall, symptomatic treatment was seen by 72% 
(Praneem) versus 78% (Ginlac-V); laboratory cure was 
achieved in 78% of each group, leading to the conclu-
sion that both regimens are valid options for treatment of 
symptomatic vaginal discharge. A major limitation to the 
study was the lack of clear and microbiologic identification 
of the causative agent of the abnormal discharge in these 
women.
With regards to recurrent bacterial vaginosis, tinidazole 
was evaluated in a case report by Baylson and colleagues.23 
The patient was a 23-year old female who had been treated 
previously with multiple courses of metronidazole gel 0.75% 
for recurrent bacterial vaginosis without successful eradica-
tion of symptoms or laboratory clearance. A regimen of oral 
tinidazole 500 mg twice daily for 14 days was given and the 
patient’s symptoms resolved and she remained asymptomatic 
for 10 months. Upon follow-up during the 10 month asymp-
tomatic period, laboratory analysis, including Gram stains, 
revealed resolution of infection.
Conclusions
Bacterial vaginosis is a problematic disease mainly effecting 
sexually active females. Tinidazole is a nitroimidazole struc-
turally related to metronidazole with some unique properties. 
In vitro comparison studies show similar activity between 
metronidazole and tinidazole against the proposed clinically 
relevant bacteria. Pharmacokinetically, the longer half-life of 
tinidazole offers some benefit in reduced dosage or frequency 
of administration compared to metronidazole. Another posi-
tive attribute of tinidazole compared to metronidazole is its 
favorable adverse event profile. However, metronidazole 
has remained the standard for the treatment of BV largely 
related to the lack of compelling head-to-head clinical com-
parisons demonstrating a benefit of either agent over the other 
and the reduced drug acquisition costs of metronidazole. 
Personal clinical experience and some case reports note 
tinidazole is an effective option in patients with refractory 
BV or recurrent BV and should be considered for patients 
with difficult to treat BV who have had multiple treatment 
regimens or suppressive therapy with either metronidazole 
or clindamycin.
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